Evolved By Nature Receives FDA Clearance for New Atopic Dermatitis Treatment Based on Innovative Peptide Platform

Evolved By Nature's Breakthrough in Atopic Dermatitis Treatment

Evolved By Nature, Inc. recently announced a groundbreaking development in the field of dermatology: the FDA's 510(k) clearance of New Day™ Skin Spray. This innovative product represents a significant advancement in the management of atopic dermatitis, a chronic condition affecting millions and characterized by damaged skin barrier function. The New Day™ Skin Spray is not just any topical application; it leverages the company's advanced programmable peptide platform, utilizing a soluble silk fibroin peptide that works effectively to address the root causes of this condition.

Atopic dermatitis is often driven by a compromised skin barrier, leading to inflammation due to irritants and allergens penetrating the skin. Most existing treatments focus on suppressing the immune response, often involving steroids and resulting in various side effects. Evolved By Nature's approach, however, emphasizes a functional barrier repair. When applied, New Day™ Skin Spray self-assembles into a flexible, breathable layer that reinforces the skin. This unique formulation disrupts the cycle of flare-ups and promotes healing from within.

Dr. Greg Altman, the Co-Founder and CEO of Evolved By Nature, elaborated on the significance of this FDA clearance. He stated, "What you're seeing in New Day™ Skin Spray is our core technology doing exactly what we built it to do, providing a foundation for real clinical utility. After spending more than a decade developing this platform, we are thrilled to witness the first product coming from it complete the rigorous regulatory process associated with medical applications. Our capacity to produce these peptides at scale is now proven, and we are set to expand into various medical avenues faster than ever aided by AI-driven enhancements."

The synergy of cutting-edge peptide technology and meticulous regulatory navigation has paved the way for New Day™ Skin Spray to reach patients. Until now, no product developed from Evolved By Nature's platform has completed this important journey, thus opening doors for future advancements in compounded medical therapies.

Evolved Health, Inc., which has spearheaded the development and commercialization of the spray, is collaborating with PHILRx, a specialty pharmacy, to ensure that this therapy reaches patients efficiently. Currently, the New Day™ Skin Spray is rolling out through select markets, with broader distribution anticipated soon. Those needing this solution will find more information available at NewDaySkinSpray.com.

About Evolved By Nature, Inc.

Evolved By Nature, headquartered in Needham, Massachusetts, focuses on maximizing the potential of natural biology to enhance healthcare and personal care products. Their peptide platform, developed over a decade, enables the production of substantial quantities of safety-tested molecules, propelling the company into the global market. Setting its sights on innovation, Evolved By Nature aims not just to assist in everyday ailments but to thrive within the burgeoning field of biologics and advanced therapies, thus utilizing AI to unlock the potential of numerous molecules.

Usage Information

It is important to note that New Day™ Skin Spray is indicated solely for treating dryness and the symptoms associated with atopic dermatitis. This medicated device should only be used under the supervision of a healthcare professional. Patients with known hypersensitivity to any ingredient in the spray are advised to avoid its use, and consultation should be sought immediately if any adverse reactions occur. The product also does not contain corticosteroids, an increasingly important attribute for those wary of long-term steroid use.

In summary, the clearance of New Day™ Skin Spray signifies a remarkable step forward in treating atopic dermatitis, with the promise of a more targeted approach that integrates innovative technology with clinical need. Patients and healthcare providers anticipate widespread availability, marking the beginning of a new era in dermatological care.